

# *Endocrine Regulation of Macronutrient Homeostasis*

Metabolism of macronutrients occurs in every cell of the body. The integrated control of these separate organs is accomplished by endocrine (and neuroendocrine) signaling pathways. This review material will cover the roles of key metabolic hormones in normal and pathological states, especially diabetes. We will cover the endocrine and neuroendocrine regulation of the gastrointestinal system in a separate lecture. This material should be a review from the endocrine unit in your undergraduate physiology courses, and the course will typically presume these concepts are familiar to you. For more details about the mechanisms of regulation, such as signal transduction, protein phosphorylation and transcriptional regulation, see the *Metabolic Control Systems* handout, also on Canvas. If there are concepts or vocabulary in these notes that are unfamiliar to you, please reach out to the instructional team as early as you can so that we can better support your success in this course.

## *Contents*

<i>Key Terms and Concepts</i>	2
<i>Mechanisms of Glucose Regulation</i>	3
<i>Pancreatic Cell Types</i>	5
<i>Key Mediators of Insulin Signaling</i>	5
<i>Glucagon Promotes Glucose Elevation</i>	6
<i>Glucagon Signal Transduction</i>	7
<i>The Primary Target of Glucagon is the Liver</i>	7
<i>Other Glucoregulatory Hormones</i>	8
<i>Pathophysiology Related to Glucose Control</i>	9
<i>Type I Diabetes Mellitus</i>	9
<i>Insulin Resistance and Type II Diabetes Mellitus</i>	9
<i>Hormonal Regulation of Protein Metabolism</i>	9
<i>Endocrine Regulators of Protein Synthesis</i>	10
<i>Hormonal Regulators of Protein Degradation</i>	10
<i>Endocrine Regulation of Lipid Metabolism</i>	11

## Key Terms and Concepts

Below is a list of some key vocabulary related to this unit. If any of these terms (or terms not listed here) are unclear or you would like defined, please use the class vocabulary page, available on Canvas.

*Metabolic Processes* These are metabolic pathways important to this class.

- Anabolism vs Catabolism
- Autophagy
- $\beta$  Oxidation
- *de novo* Lipogenesis
- Gluconeogenesis
- Glucose Oxidation, including Glycolysis and the TCA<sup>1</sup> Cycle and Oxidative Phosphorylation
- Glucose Uptake, including Insulin Stimulated Glucose Uptake
- Glycogenesis and Glycogenolysis
- Insulin Secretion
- Ketogenesis and Ketoacidosis
- Lipolysis
- Proteolysis
- Triglyceride Synthesis

<sup>1</sup> Tricarboxylic Acid Cycle, also known as the Krebs's Cycle or Citric Acid Cycle

*Hormones* You should be familiar with where these hormones come from, and when they are elevated.

- Adrenaline, also known as Epinephrine<sup>2</sup>
- Cortisol
- Glucagon
- Growth Hormone
- Insulin
- Insulin-Like Growth Factor 1 (IGF-1)

<sup>2</sup> Along with norepinephrine/norepinephrine

*Protein Kinases* These are proteins that phosphorylate other proteins and lead to post-translational regulation<sup>3</sup>. You should be familiar with what hormones regulate these kinases, and over the course of the semester how they control metabolism.

- Akt<sup>4</sup>
- AMP-Activated Protein Kinase (AMPK)
- Glycogen Synthase Kinase 3 (GSK3)
- Protein Kinase A (PKA)

<sup>3</sup> A *kinase* is an enzyme that adds a phosphate group to a molecule, a *protein kinase* is an enzyme that adds a phosphate group to another protein. These reactions are reversed by enzymes called *phosphatases*

<sup>4</sup> Also referred to as Protein Kinase B

- Mechanistic Target of Rapamycin Complex 1 (mTORC1)

*Transcription Factors* . These regulate gene transcription, or the production of new proteins. This typically is much slower than allosteric or post-translational regulation.

- cAMP-Response Element Binding Protein (CREB)
- Glucocorticoid Receptor
- FOXO<sup>5</sup>
- Sterol Response Element Binding Protein (SREBP)

<sup>5</sup> A family of Forkhead Box proteins

### *Mechanisms of Glucose Regulation*

GLUCOSE IS TYPICALLY MAINTAINED IN A VERY NARROW RANGE, between 4.4 to 6.1 mmol/L. The major tissues responsible for regulating glucose levels are listed in Table 1. Glucose levels need to be re-established after changes in feeding status, or energy utilization or elevated during the absence of dietary carbohydrates. In general, when glucose levels decrease, glucagon is released from alpha cells of the pancreas to promote glucose production, either from glycogen breakdown or gluconeogenesis. Alternately, after a meal when glucose levels increase, insulin is secreted from beta cells of the pancreas causing glucose levels in the blood to decrease.

For the purposes of the acute maintenance of glucose homeostasis, four organs are the most important; the pancreas, liver, muscle and adipose tissue. After a meal, glucose is the primary site of glucose disposal [DeFronzo et al., 1981]. The inability to clear glucose from the bloodstream and into muscle is one major cause of the hyperglycemia associated with type 2 diabetes<sup>6</sup>.

GLUCOSE ENTERS THE CELL, DOWN A CONCENTRATION GRADIENT via passive transport from the blood into most tissues including liver, pancreas, kidneys and the brain. In these cases the passive transport of glucose into the cell is mostly unregulated. However, for glucose to enter into muscle and fat tissue, insulin is required. This is accomplished by moving GLUT4 transporters from intracellular storage sites to the plasma membrane, allowing for glucose influx. Once inside the cell, insulin will promote both glycogenesis and glycolysis.

GLUCOSE CAN BE STORED AS GLYCOGEN<sup>7</sup>. To form glycogen, glucose must first be converted through glucose-1-phosphate into UDP-glucose. This activated form of glucose is then added onto existing

Table 1: Primary sites for regulation of glucose homeostasis

Process	Tissue
Insulin Stimulated Glucose Uptake	Muscle and Fat
Glucose Oxidation	Muscle, Brain
Glycogen Storage/Release	Liver and Muscle
Gluconeogenesis	Liver

<sup>6</sup> The other proximal cause is unrestrained gluconeogenesis.

<sup>7</sup> This is known as glycogenesis

glycogen chains through the activity of an enzyme named glycogen synthase. As we will discuss later in the semester, in addition to being regulated by protein phosphorylation and sub-cellular location, glycogen synthase is also allosterically activated by glucose-6-phosphate, promoting increased glycogen synthesis when glucose levels<sup>8</sup> in the cell are high. The combination of the allosteric and post-translational signals mean that when insulin levels are high, glycogenesis is promoted.

<sup>8</sup> and therefore G6P levels

TO LIBERATE GLUCOSE FROM STORED GLYCOGEN, AN ENZYME KNOWN AS GLYCOGEN PHOSPHORYLASE IS ACTIVATED. This enzyme hydrolyses glycogen, releasing glucose-1-phosphate, which can then be dephosphorylated into glucose for glycolysis or release into the blood stream. Hepatic glycogenolysis is the preferred source of short term glucose maintenance. In addition to post-translational modifications and recruitment to the glycogen pellet by accessory proteins, glycogen phosphorylase is allosterically activated by energy stress such as increases in AMP, or negatively by increases in glucose-6-phosphate levels. When adrenaline<sup>9</sup> is elevated, glycogenolysis occurs releasing stored glucose for energy or to maintain normoglycemia.

<sup>9</sup> or for the liver, glucagon as well.

GLUCONEOGENESIS IS THE GENERATION OF GLUCOSE FROM NON-CARBOHYDRATE PRECURSOR MOLECULES. These typically include amino acids, lactate and glycerol<sup>10</sup>. The majority of gluconeogenesis occurs in the liver, and generally is important for glucose production from proteins and lipids after glycogen stores are depleted. This biochemistry of gluconeogenesis is similar to reversed glycolysis though in several cases different enzymes are used. As we will discuss later in the lecture, the rate limiting enzymes in gluconeogenesis are phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase and glucose-6-phosphatase. These enzymes are under both transcriptional and post-translational control as described below. Both the supply of gluconeogenic precursors (via breakdown of triglycerides and proteins), as well as the activity of gluconeogenic enzymes are reduced by insulin. Adrenaline and glucagon both *prevent* glycolysis in the liver (but not the muscle). This is to make sure that the glucose that is produced via gluconeogenesis isn't catabolized back to energy.

<sup>10</sup> Along with free fatty acids, the products of triglyceride breakdown, also known as *lipolysis*.

WHEN ENERGY IS NEEDED, for example during fasting, the primary source is circulating glucose, followed by the breakdown of glycogen and then the production of new glucose (gluconeogenesis) from proteins and lipids. At the same time, the unnecessary synthesis of new glycogen is stopped. When glucose levels are too high, the first

response is uptake and oxidation by the muscle, followed by glycogen synthesis and then eventually by *de novo* lipogenesis. At this time, gluconeogenesis (which is not needed) is stopped. A summary of how insulin and adrenaline function to control these processes is shown in Table 3.

### *Pancreatic Cell Types*

In order to balance the energy requirements of all tissues, blood glucose is primarily controlled via endocrine and neuroendocrine mechanisms. The primary mediators are insulin and glucagon which are secreted from the pancreas during times of hyper and hypoglycemia respectively. These two peptide hormones are released from two cell types in the pancreas, the  $\alpha$  cells which release glucagon and the  $\beta$  cells which release insulin. Both cell types are located in the Islets of Langerhans within the pancreas (see Figure 1).




Table 2: Primary functions of insulin and the adrenergic hormones, glucagon and adrenaline on glucose homeostasis.

Process	Insulin	Adrenergic
Insulin Stimulated Glucose Uptake	↑	-
Glycolysis - Liver	↑	↓
Glycolysis - Muscle/Brain	↑	-
Glycogenolysis	↓	↑
Gluconeogenesis	↑	↓
Lipolysis	↓	↑

Figure 1: Schematic of a pancreatic islet. Taken from Efrat and Russ [2012]

### *Key Mediators of Insulin Signaling*

Insulin was discovered by Frederick Banting and his colleagues at the University of Toronto in 1921. They performed experiments in which they injected extracts from pancreas fractions into dogs which had their pancreas' surgically removed. They showed that a secreted substance from the pancreas lowered blood glucose in these dogs [Banting et al., 1922]. They were then able to confirm that this treatment was also effective in children with type 1 diabetes. This work led to Banting and John Macleod winning the Nobel Prize in Medicine and Physiology in 1923. We now know that type 1 diabetes is caused by

autoimmune destruction of the pancreatic beta cells<sup>11</sup>. On the other hand type 2 diabetes, often associated with obesity, is a *peripheral resistance* to the effects of insulin. This occurs when the muscle and liver stop responding to insulin.

<sup>11</sup> At this stage you should be able to predict how the lack of insulin affects glucose disposal, gluconeogenesis, and lipolysis

The majority of the actions of insulin are mediated by a protein kinase called Akt (see [Manning and Cantley, 2007] for more details). This protein kinase is activated downstream of both the insulin and IGF1 receptor. Loss of function mutations in one of the isoforms, *AKT2* in humans results in dramatic peripheral insulin resistance [George et al., 2004]<sup>12</sup>. Akt, once activated by insulin or IGF1 can phosphorylate a variety of proteins including key metabolic enzymes, but also activates key signaling cascades. Three important cascades we will discuss that function downstream of Akt are FOXO and GSK3 (which are inactivated by Akt) and mTORC1 (which is activated).

<sup>12</sup> These mutations are quite rare in the general population.

THE LIVER IS A KEY CENTRAL NODE OF METABOLISM. The liver is often the first destination for nutrients that are absorbed in the gut and is a key site of storage and interconversion of nutrients. For a more detailed review of liver function we recommend the recent review by Trefts et al. [2017]. Effective liver function is central to many key processes including lipid transport, amino acid oxidation and glucose homeostasis. In concert with increases in obesity, the prevalence of non-alcoholic fatty liver disease<sup>13</sup> has been dramatically increasing [Hashimoto and Tokushige, 2011]. Impaired liver function renders us less able to interconvert and dispose of macronutrients, and less able to detoxify harmful compounds.

<sup>13</sup> This is often abbreviated as NAFLD.

### *Glucagon Promotes Glucose Elevation*

When glucose levels are low, glucagon is released from alpha cells in the pancreas. This promotes the breakdown of glycogen stores in liver and muscle, and the generation of glucose from gluconeogenic precursors. Glucagon receptors exist mainly in the liver, so glucagon does not exert its main catabolic effects on either adipose or muscle tissue.

The mechanisms which underlie hypoglycemia induced glucagon release are incompletely understood. What is clear however, is that when blood glucose levels decrease, glucagon is released from the alpha cells of the pancreas into the portal vein.

### *Glucagon Signal Transduction*

Adrenergic-receptor coupled mediated cAMP synthesis was the first example of a hormonal second messenger. Earl Sutherland was interested in the regulation of glycogenolysis and he noticed that if he added adrenaline to intact cells, he could accelerate glycogen breakdown, but if he added it to lysed cells he could not. In his key experiment he treated one set of livers with adrenaline, then lysed them. He then added that lysate to a second set of livers which had already been broken. He found that there was an internal factor (later identified as cAMP) in the stimulated tissues, that could accelerate glycogenolysis in the other tissues [Rall et al., 1956]. For this work, Sutherland won the Nobel Prize in Medicine and Physiology in 1971.

In metabolism, the main effector of cAMP in cells is Protein Kinase A (PKA). This protein kinase is allosterically activated by cAMP and phosphorylates a wide variety of important metabolic substrates. The identification of PKA and its role in carbohydrate homeostasis led to Fisher and Krebs winning the Nobel Prize in Medicine and Physiology in 1992. The primary role of glucagon is to increase blood glucose, both by mobilizing glycogen stores and inducing gluconeogenesis. The mechanisms for this are identical to those for adrenaline, as both of these hormones activate Gs-linked receptors and result in PKA activation in the liver.

### *The Primary Target of Glucagon is the Liver*

As described above, glucagon stimulates the breakdown of glycogen. This proceeds via protein phosphorylation of both glycogen phosphorylase (which activates the enzyme) and glycogen synthase (which inactivates the enzyme). In combination, this leads to a breakdown of glycogen into glucose.

PKA is the primary mediator of the activation of glycogen phosphorylase. Once activated by adrenergic signaling, PKA phosphorylates and activates glycogen phosphorylase kinase. This kinase in turn, phosphorylates and activates glycogen phosphorylase [Krebs and Fischer, 1956]. PKA also directly phosphorylates glycogen synthase, which in concert with the activation of the other glycogen synthase kinases (notably GSK3 and AMPK) leads to increased phosphorylation and inactivation of glycogen synthase.

In addition to the activation of these protein kinases, there is a reduction of glycogen associated protein phosphatase activity. As a balance, this leads to more highly phosphorylated and therefore more glycogenolytic activities.

GLUCAGON ALSO PROMOTES GLUCONEOGENESIS IN THE LIVER.

There are both post-translational and transcriptional mechanisms by which adrenergic signaling promotes gluconeogenesis. Similar to glycolysis, the allosteric and post-translational regulation of gluconeogenesis is rapid, while the transcriptional regulation is slower but more stable.

Post-translationally, the best studied route by which PKA activates gluconeogenesis is through inactivation of phosphofructokinase-2. PFK-2 normally generates the carbohydrate Fructose-2,6-bisphosphate which is a positive regulator of glycolysis and a negative regulator of gluconeogenesis. The alleviation of this inhibition allows for promotion of the gluconeogenic metabolism.

Transcriptionally, the transcription factor CREB is phosphorylated by PKA where it plays a role in transcriptionally activating the rate limiting gluconeogenic enzymes PEPCK, FBPase and G6Pase. This is energetically costly, and occurs slowly. Transcriptional changes are therefore often more permanent in nature.

### *Other Glucoregulatory Hormones*

Since glucagon works primarily on liver tissue, different hormonal messengers function to stimulate catabolism of lipid in muscle and fat tissue. A key difference from adrenaline and glucagon, is that adrenaline also has major effects on fat and muscle tissues, as well as glycogen. Therefore, in addition to stimulating hepatic gluconeogenesis and glycogenolysis, adrenaline also promotes lipid release and muscle glucose oxidation. Both adrenaline and glucagon function by stimulating adrenergic signaling and cAMP-dependent PKA activation. Some similarities and differences between glucagon and adrenaline are shown in Table ??.

In adipose tissue, adrenaline induces lipolysis, via phosphorylation and activation of Hormone Sensitive Lipase (HSL), Perilipin and Adipocyte Triglyceride Lipase (ATGL). These proteins function to mobilize triglycerides into free fatty acids for use in other tissues, especially muscle. For more information on the regulation of lipolysis, see [Young and Zechner, 2013]. At an acute level, these do not contribute much to glucose homeostasis but are extremely important for lipid metabolism.

LONGER TERM GLUCOSE CONTROL IS REGULATED BY TWO OTHER HORMONES PREVIOUSLY DISCUSSED, GROWTH HORMONE AND CORTISOL. These hormones are elevated during times of growth or stress where it is important to keep circulating glucose available for other functions. During a prolonged fast, both GH and cortisol can be released, causing longer-lasting changes which ensure adequate blood

Table 3: Comparison between glucagon and adrenaline. Glucagon does not promote lipolysis, think about why that might be the case.

	Glucagon	Adrenaline
Source	Pancreas	Adrenal
Signal	Hypoglycemia	Acute Stress
Receptors	Liver	Widespread
Signaling Pathway	PKA	PKA
Gluconeogenesis	↑	↑
Hepatic Glycolysis	↓	↓
Lipid Oxidation	↑	↑
Lipolysis	-	↑



supply to the brain.

INCRETINS ENHANCE INSULIN RELEASE, and are typically released from the gut. They were first described when it was noted that when equal amounts of glucose are provided either through the gut, or intravenously, the gut-supplied glucose leads to a more robust insulin secretion effect. Eventually to gut-derived peptide hormones, GLP-1 and GIP<sup>14</sup> were described. Both of these peptides are degraded by an enzyme called DPP-4, and inhibitors of this process have provided an exciting new potential therapeutic mechanism for enhancing glucose control.

<sup>14</sup> glucagon-like peptide 1 and gastric inhibitory peptide respectively

## *Pathophysiology Related to Glucose Control*

### *Type I Diabetes Mellitus*

Type I Diabetes is typically caused by autoimmune destruction of pancreatic beta cells. Without these cells, the pancreas is unable to produce insulin and without careful monitoring and exogenous insulin, blood glucose levels will rise. At the same time, lipolysis is very high. The excess flow of fatty acids into a liver which is unable to oxidize them<sup>15</sup> results in the production of ketone bodies, which when uncontrolled can lead to diabetic ketoacidosis.

<sup>15</sup> We will discuss this in much more detail when we talk about lipid oxidation, but because the liver is diverting TCA cycle intermediates towards gluconeogenesis, the TCA cycle is unable to oxidize Acetyl-CoA. This results in Acetyl-CoA being converted into a ketone and released from the cell. The biochemistry is similar to nutritional ketosis, except in that case ketone levels are not typically elevated as high.

### *Insulin Resistance and Type II Diabetes Mellitus*

Type II diabetes occurs as a result of a multi-step process starting with negative feedback loops on insulin signaling. As more nutrients are stored, for example in obesity metabolic tissues become resistant to the effects of insulin, likely as a way to protect against excessive lipid storage.

As tissues become more insulin resistant, more insulin must be secreted by the pancreas to maintain normoglycemia. If insulin resistance proceeds, more and more insulin will need to be produced and secreted by beta cells. Eventually the beta cells will be unable to keep up with this demand and glucose levels will rise as the amount of endogenous or exogenous insulin is less and less effective.

## *Hormonal Regulation of Protein Metabolism*

Protein homeostasis is an important ongoing process that is regulated both at the level of *protein synthesis* and *protein degradation*. Protein synthesis is especially important in the context of growth and development.

### *Endocrine Regulators of Protein Synthesis*

There are several hormone that control protein synthesis, often mediated by a protein kinase called mTORC1. This kinase promotes protein synthesis by increasing the rates of initiation of translation, and the rates of peptide chain elongation. For more details about how mTORC1 regulates protein production, we recommend this review[Gingras et al., 2004].

INSULIN AND INSULIN-LIKE GROWTH FACTOR (IGF) ARE POTENT ACTIVATORS OF PROTEIN SYNTHESIS. Insulin, as described above is secreted by the  $\beta$  cells of the pancreas by increased blood glucose. Elevations in amino acids, such as leucine and alanine are also potent activators of insulin secretion [Floyd et al., 1966]. Insulin-like Growth Factor 1, on the other hand is produced in the liver and is regulated both nutritionally, and by Growth Hormone (GH)<sup>16</sup>. Both insulin and IGF1<sup>17</sup> activate receptors in peripheral tissues to promote protein production. Insulin and IGF1, along with other signals such as elevations in the amino acids Leucine, Lysine or Arginine lead to mTORC1 activation which promotes the synthesis of proteins.

ANOTHER MAJOR REGULATOR OF PROTEIN SYNTHESIS IS GROWTH HORMONE. Growth hormone is released from the somatotroph cells in the anterior pituitary. The two primary regulators of GH secretion are the hypothalamic hormones GHRH<sup>18</sup> and somatostatin<sup>19</sup> Growth hormone is highest during youth while people are actively growing. As a person ages, the amount of growth hormone decreases. Growth hormone also undergoes a normal diurnal rhythm. GH levels are highest shortly after going to sleep and lower during the day. Because of this, most growth occurs during sleeping when nutrients can be used for growth and are not needed for normal activities. This hormone has two main functions:

1. Direct actions on bone, muscle, adipocytes and liver tissue via its own receptor<sup>20</sup>.
2. Indirect actions by promoting the release of IGF1 from the liver. This helps to promote anabolism in muscle and bone.

### *Hormonal Regulators of Protein Degradation*

Protein breakdown occurs via two mechanisms, proteolysis which targets specific proteins for degradation and autophagy<sup>21</sup> which can target entire organelles. Both of these processes result in the liberation of amino acids from proteins. Unlike fatty acids (triglycerides) and glucose (glycogen) there is no standard storage molecule for

<sup>16</sup> The GH/IGF1 axis will be described in the next section.

<sup>17</sup> There is very little IGF1 activity on adipocytes, so it does not have a strong anti-lipolytic role.

<sup>18</sup> Growth Hormone Releasing Hormone.

<sup>19</sup> Sometimes called growth hormone inhibiting hormone or GHIH.

<sup>20</sup> In general these functions serve to direct substrates (fatty acids, amino acids and carbohydrates) from storage tissues such as liver and adipose towards growing tissues such as muscle and bone.

<sup>21</sup> or self-eating

amino acids, so when the body needs amino acids, a variety of proteins are catabolized.

ONE MAJOR PATHWAY BY WHICH PROTEOLYSIS IS SUPPRESSED IS THE INSULIN/IGF-FOXO PATHWAY. Akt-dependent signaling in insulin and IGF<sub>1</sub> *reduce* FOXO activity (see Figure 2). When active, FOXO transcriptionally activates proteolytic genes known as atrogenes to liberate amino acids. These amino acids may be liberated for fuel, or to provide building blocks for gluconeogenesis. Therefore, when insulin/IGF signaling is active, proteolysis is reduced.

CORTISOL FUNCTIONS TO MAKE BLOOD GLUCOSE AVAILABLE TO KEY ORGANS SUCH AS THE BRAIN, DURING TIMES OF STRESS. As such, cortisol promotes gluconeogenesis, by transcriptionally activating several enzymes, including G6Pase, PEPCK and pyruvate carboxylase. At the same time, cortisol promotes delivery of gluconeogenic precursors such as glycerol (from adipocyte lipolysis), lactate and alanine (from muscle tissue) to the liver. Chronically elevated cortisol leads to substantial muscle breakdown and is a major side effect of prescribed glucocorticoids or chronic stress. This is described in Figure ??, based on this you might be able to make a prediction of how insulin resistance might affect glucose production and proteolysis.




Figure 2: Schematic of regulation of FOXO and its role in proteolysis and gluconeogenesis.

### *Endocrine Regulation of Lipid Metabolism*

Lipid synthesis promoted by insulin and reversed by adrenaline. Triglyceride breakdown can be thought of in two phases, the conversion of triglycerides into fatty acids and glycerol<sup>22</sup> and then the conversion of these fatty acids into energy<sup>23</sup>.

INSULIN FUNCTIONS TO PROMOTE LIPID STORAGE in two ways. It promotes the production of lipids from precursors<sup>24</sup>, promotes the esterification of fatty acids and glycerol into triglycerides and prevents the breakdown of triglycerides into fatty acids. We will discuss the mechanisms by which insulin controls fat storage later in the semester.

TO LIBERATE AND USE LIPIDS FOR FUEL first, fatty acids are released from adipose tissue, with the activation of  $\beta$ -oxidation happening concurrently in muscle. There are several hormones that regulate this, but adrenaline, which promotes both adipocyte lipolysis and muscle lipid oxidation is very important as is the energy sensor AMPK. As we will learn later in the semester, several key lipolytic

<sup>22</sup> This is known as lipolysis and releases fatty acids and glycerol from stored triglycerides.

<sup>23</sup> This is known as fatty acid oxidation or  $\beta$ -oxidation.

<sup>24</sup> This is known as *de novo* lipogenesis.

and oxidative enzymes are activated by adrenaline (and PKA) mediated protein phosphorylation.

## References

F. G. Banting, C. H. Best, J. B. Collip, W. R. Campbell, and A. A. Fletcher. Pancreatic Extracts in the Treatment of Diabetes Mellitus. *Canadian Medical Association journal*, 12(3):141–6, mar 1922. ISSN 0008-4409. DOI: 10.1097/00005053-192401000-00013. URL <http://pubmed.org/20314060>.

Ralph A. DeFronzo, Ele Ferrannini, Y Sato, P Felig, and J Wahren. Synergistic interaction between exercise and insulin on peripheral glucose uptake. *The Journal of clinical investigation*, 68(6):1468–74, dec 1981. ISSN 0021-9738. URL <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=370949&tool=pmcentrez&rendertype=abstract>.

Shimon Efrat and Holger a. Russ. Making  $\beta$  cells from adult tissues. *Trends in Endocrinology & Metabolism*, 23(6):278–285, 2012. ISSN 10432760. DOI: 10.1016/j.tem.2012.03.005. URL <http://linkinghub.elsevier.com/retrieve/pii/S1043276012000495>.

J C Floyd, S S Fajans, J W Conn, R F Knopf, and J Rull. Stimulation of insulin secretion by amino acids. *The Journal of clinical investigation*, 45(9):1487–502, sep 1966. ISSN 0021-9738. DOI: 10.1172/JCI105456. URL <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=292828&tool=pmcentrez&rendertype=abstract>.

Stella George, Justin J. Rochford, Christian Wolfrum, Sarah L. Gray, Sven Schinner, Jenny C. Wilson, Maria A. Soos, Peter R. Murgatroyd, Rachel M. Williams, Carlo L. Acerini, David B. Dunger, David Barford, A. Margot Umpleby, Nicholas J. Wareham, Huw Alban Davies, Alan J. Schafer, Markus Stoffel, Stephen O’Rahilly, and Ines Barroso. A Family with Severe Insulin Resistance and Diabetes Mellitus due to a Missense Mutation in AKT2. *Science (New York, N.Y.)*, 304(5675):1325–1328, 2004. ISSN 0036-8075. DOI: 10.1126/science.1096706. URL <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258004/{%}5Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258004/pdf/ukmss-1515.pdf>.

A C Gingras, B Raught, and Nahum Sonenberg. mTOR signaling to translation. *Current topics in microbiology and immunology*, 279:169–97, jan 2004. ISSN 0070-217X. URL <http://www.ncbi.nlm.nih.gov/pubmed/14560958>.

Etsuko Hashimoto and Katsutoshi Tokushige. Prevalence, gender, ethnic variations, and prognosis of NASH. *Journal of Gastroenterology*, 46:63–69, 2011. ISSN 09441174. DOI: 10.1007/s00535-010-0311-8.

E. G. Krebs and E H Fischer. The phosphorylase b to a converting enzyme of rabbit skeletal muscle. *Biochimica et biophysica acta*, 20(1): 150–7, apr 1956. ISSN 0006-3002. URL <http://www.ncbi.nlm.nih.gov/pubmed/13315361>.

Brendan D. Manning and Lewis C. Cantley. AKT/PKB Signaling: Navigating Downstream. *Cell*, 129(7):1261–1274, jun 2007. ISSN 00928674. DOI: 10.1016/j.cell.2007.06.009. URL <http://linkinghub.elsevier.com/retrieve/pii/S0092867407007751>.

T W Rall, E W Sutherland, and W D Wosilait. The relationship of epinephrine and glucagon to liver phosphorylase. III. Reactivation of liver phosphorylase in slices and in extracts. *The Journal of biological chemistry*, 218(1):483–95, jan 1956. ISSN 0021-9258. URL <http://www.ncbi.nlm.nih.gov/pubmed/13278355>.

Elijah Trefts, Maureen Gannon, and David H. Wasserman. The liver. *Current Biology*, 27(21):R1147–R1151, 2017. ISSN 09609822. DOI: 10.1016/j.cub.2017.09.019.

Stephen G Young and Rudolf Zechner. Biochemistry and pathophysiology of intravascular and intracellular lipolysis. *Genes & development*, 27(5):459–84, mar 2013. ISSN 1549-5477. DOI: 10.1101/gad.209296.112. URL <http://dx.doi.org/10.1101/gad.209296.112>.